|
|
|
|
 |
| |
Why Keep Patients on COMBIVIR?
Continuing the Present Therapy with COMBIVIR
You should consider keeping stable patients currently taking COMBIVIR on COMBIVIR. COMBIVIR may allow freedom of choice in future drug options should the COMBIVIR regimen eventually fail.1
- Indicated for use in combination with other antiretrovirals for the treatment of HIV infection
- Fixed-dose combination taken as 1 pill BID
- No food or fluid restrictions
- No known significant drug interactions with NNRTIs or PIs
- Particularly convenient if third drug is also dosed BID
COMBIVIR: Studied for Over a Decade in Clinical Trials
- COMBIVIR or its components, ZDV+3TC, have been studied in over 18,000 patients in over 50 randomized, controlled clinical trials
- 10 were conducted by competitors to support their products for FDA approval
- Recent trials
- ACTG50952 COM+EFV
- CNA300243 COM+EFV
- ACTG3844 COM+EFV or NFV
- CNA30145 COM+IDV
- BMS 1526 COM+NFV
- Pivotal trials
- DuPont 0067 COM+EFV
- Merck 0358 COM+IDV
- Agouron 5119 COM+NFV
- PROAB 300110 COM+APV
- BMS 03411 COM+ATV
The Most Prescribed NRTI Backbone
- COMBIVIR or its components are contained in many of the most-prescribed regimens for all patients on therapy12
- COMBIVIR is a preferred NRTI backbone in both the DHHS and IAS-USA Guidelines1,13
Durable Efficacy of COMBIVIR
| COMBIVIR plus |
Patient population |
Follow-up |
EFV or NFV
ACTG3844 |
n=310
ART naive |
2+ years |
EFV
DuPont 0067
|
n=422
PI, NNRTI, 3TC naive |
3 years |
NFV
Agouron 5119 |
n=55
ART naïve |
4 years |
IDV
Merck 0358 |
n=33
ZDV experienced |
6 years |
| References |
| | 1. | US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 6, 2005. Available at http://aidsinfo.nih.gov/guidelines. Accessed February 24, 2006. |
| | 2. | Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 Infection. N Engl J Med. 2004;350:1850-1861. |
| | 3. | DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39:1038-1046. |
| | 4. | Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-2303. |
| | 5. | Vibhagool A, Cahn P, Schechter M, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: Results of a 48-week open-label, equivalence trial (CNA3014). Current Medical Research and Opinion. 2004;20:1103-1114. |
| | 6. | Videx® EC (didanosine) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; October 2005. |
| | 7. | Tashima K, Staszewski S, Nelson M, et al. Durable viral suppression on EFV-based HAART; 168 weeks of follow-up. 15th International AIDS Conf. 2004: Poster TuPeB4547. |
| | 8. | Gulick R, Meibohm A, Havlir D, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS. 2003; 17(16):2345-2349. |
| | 9. | Gathe J Jr, Chu A, Yuen N, et al. Durability of nelfinavir combination therapy after 4 years: 3-year extension data from Agouron Study 511. In: Abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; October 28-31, 2001; Athens, Greece. Poster LB10. |
| | 10. | Agenerase® (amprenavir) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; May 2005. |
| | 11. | Reyataz™ (atazanavir sulfate) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; January 2006. |
| | 12. | Synovate 2005, Q3. |
| | 13. | Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA Panel. JAMA. 2006; 296:827-843. |
|
|
|
|
|
